cyc 202 has been researched along with alvocidib in 50 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (alvocidib) | Trials (alvocidib) | Recent Studies (post-2010) (alvocidib) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 627 | 66 | 204 |
| Protein | Taxonomy | cyc 202 (IC50) | alvocidib (IC50) |
|---|---|---|---|
| Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | 1 | |
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.36 | |
| [Tau protein] kinase | Sus scrofa (pig) | 0.36 | |
| Cyclin-T1 | Homo sapiens (human) | 0.0243 | |
| Cyclin-K | Homo sapiens (human) | 1.37 | |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | 8 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.1571 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.36 | |
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | 1.2 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 7.6 | |
| Vitamin K-dependent protein C | Homo sapiens (human) | 0.1429 | |
| Protein kinase C gamma type | Homo sapiens (human) | 8 | |
| Protein kinase C beta type | Homo sapiens (human) | 8 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1159 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.1589 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1464 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.2067 | |
| Protein kinase C alpha type | Homo sapiens (human) | 6.2667 | |
| Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.185 | |
| Cyclin-A2 | Homo sapiens (human) | 0.3441 | |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 1.3 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1837 | |
| Protein kinase C eta type | Homo sapiens (human) | 8 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.2249 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.2367 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.1 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.1983 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
| Protein kinase C iota type | Homo sapiens (human) | 8 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.525 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.6517 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.3365 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0209 | |
| Cyclin-H | Homo sapiens (human) | 0.3413 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.514 | |
| Cyclin-A1 | Homo sapiens (human) | 0.785 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1572 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1747 | |
| Cyclin homolog | Herpesvirus saimiri (strain 11) | 0.185 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 5.4933 | |
| Protein kinase C theta type | Homo sapiens (human) | 8 | |
| Protein kinase C zeta type | Homo sapiens (human) | 8 | |
| Protein kinase C delta type | Homo sapiens (human) | 5.63 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1765 | |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | 8 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | 0.3 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.1571 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.2067 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 1.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.00) | 18.2507 |
| 2000's | 21 (42.00) | 29.6817 |
| 2010's | 20 (40.00) | 24.3611 |
| 2020's | 6 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfield, PA; Boylan, JF; Sielecki, TM; Trainor, GL | 1 |
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Akula, N; Pattabiraman, N; Sridhar, J | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Aboagye, EO; Ali, S; Alikian, M; Barbazanges, M; Barrett, AG; Blum, A; Brackow, J; Coombes, RC; Freemont, PS; Fuchter, MJ; Hazel, P; Heathcote, DA; Jogalekar, AS; Kanneganti, SK; Kroll, SH; Liotta, DC; Pace, RD; Patel, H; Periyasamy, M; Scheiper, B; Siwicka, A; Snyder, JP | 1 |
| Bártek, J; Havlícek, L; Jorda, R; Krystof, V; Kuzma, M; McNae, IW; Mistrík, M; Navrátilová, J; Strnad, M; Sturc, A; Voller, J; Walkinshaw, MD | 1 |
| Russu, WA; Shallal, HM | 1 |
| Abrol, R; Goddard, WA; Kudo, W; Nair, N; Reddy, VP; Smith, MA | 1 |
| Baumli, S; Endicott, JA; Fischer, PM; Hole, AJ; Huang, S; Noble, ME; Pepper, C; Shao, H; Shi, S; Wang, S | 1 |
| Abbas, AY; Baumli, S; Endicott, JA; Fischer, PM; Foley, DW; Hole, AJ; Huang, S; Lam, F; Liu, X; Noble, M; Pepper, C; Shao, H; Shi, S; Wang, S | 1 |
| Akula, B; Athuluridivakar, S; Baker, SJ; Bharathi, EV; Billa, VK; Cosenza, SC; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR; Vasquez-Del Carpio, R | 1 |
| Joshi, G; Kalra, S; Kumar, R; Munshi, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Marzaro, G; Poratti, M | 1 |
| Cui, S; Galons, H; Huang, Y; Ingarra, AM; Li, T; Lu, K; Oumata, N; Teng, Y; Yu, P; Zhang, Q; Zhao, L | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Chen, K; Jiang, H; Li, J; Li, Y; Lin, T; Liu, L; Luo, C; Xu, P; Zhou, B | 1 |
| Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
| Coffey, ET; Courtney, MJ | 1 |
| Chang, TH; Lee, HR; Senderowicz, AM; Szabo, E; Tebalt, MJ | 1 |
| Détivaud, L; Doerig, C; Gray, N; Meijer, L | 1 |
| Gelman, IH; Klotman, PE; Nelson, PJ | 1 |
| Conrad, D; Dai, Y; Dent, P; Grant, S; Krystal, G; Rahmani, M; Yu, C | 1 |
| Bravo, R; Bruna, A; Caelles, C; Camarasa, J; Camins, A; Canudas, AM; Escubedo, E; Jiménez, A; Jorda, EG; Pallàs, M; Pubill, D; Verdaguer, E | 1 |
| Doniger, J; Mayner, R; Sadaie, MR | 1 |
| Canduri, F; de Azevedo, WF; Uchoa, HB | 1 |
| Cress, WD; Freeman, SN; Ma, Y | 1 |
| Blagden, S; de Bono, J | 1 |
| Fischer, PM; Gianella-Borradori, A | 1 |
| Byrnes, KR; Cernak, I; Di Giovanni, S; Faden, AI; Stoica, B | 1 |
| Bamba, D; Davis, C; Gallo, RC; Gwarzo, MY; Heredia, A; Le, N; Redfield, RR; Sadowska, M | 1 |
| Schmid, G; Wesierska-Gadek, J | 1 |
| André, P; Appert-Collin, A; Coupin, G; Gies, JP; Hugel, B; Levy, R; Lombard, Y; Niederhoffer, N; Poindron, P | 1 |
| Berro, R; Chao, SH; de la Fuente, C; Kashanchi, F; Nekhai, S; Pumfery, A | 1 |
| Bensaude, O; Biglione, S; Byers, SA; Maury, W; Nguyen, VT; Price, DH; Price, JP | 1 |
| Chen, XG; Zuo, MX | 1 |
| Chen, R; Chubb, S; Fox, JA; Gandhi, V; Hawtin, RE; Keating, MJ; Plunkett, W; Wierda, WG | 1 |
| De Clercq, E; Liu, XY; Wang, Y | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Auladell, C; Beas-Zarate, C; Camins, A; de la Torre, AV; Folch, J; Junyent, F; Pallàs, M; Pelegrí, C; Verdaguer, E; Vilaplana, J | 1 |
| Hampson, P; Hazeldine, J; Krystof, V; M, J; Pechan, P; Strnad, M; Wang, K | 1 |
| Beider, K; Josefsberg Ben-Yehoshua, L; Nagler, A; Ostrovsky, O; Peled, A; Samookh, M; Shimoni, A | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Giordano, A; Morales, F | 1 |
| Adiyasa, I; Cano, C; Hardcastle, IR; Heptinstall, AB | 1 |
| Cwiklinski, E; Hoffmann, TM; Hundal, HS; Hyde, R; Lipina, C; Stretton, C; Taylor, PM | 1 |
18 review(s) available for cyc 202 and alvocidib
| Article | Year |
|---|---|
Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.
Topics: Animals; Cell Cycle; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Models, Molecular | 2000 |
Selectivity and potency of cyclin-dependent kinase inhibitors.
Topics: Animals; Binding Sites; Cyclin-Dependent Kinases; Humans; Protein Kinase Inhibitors; Signal Transduction | 2006 |
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Topics: Aminopyridines; Benzimidazoles; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Structure-Activity Relationship | 2019 |
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Development; Humans; Protein Kinase Inhibitors; Pyrimidines; Triazines | 2019 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
ATP-site directed inhibitors of cyclin-dependent kinases.
Topics: Adenine; Adenosine Triphosphate; Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Cell Cycle; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Flavonoids; Humans; Isopentenyladenosine; Kinetin; Molecular Sequence Data; Piperidines; Purines; Roscovitine; Sequence Alignment; Sequence Homology, Amino Acid; Staurosporine; Suramin | 1999 |
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.
Topics: Anti-HIV Agents; Antimetabolites; Antineoplastic Agents; Apoptosis; Camptothecin; Cyclin-Dependent Kinases; Flavonoids; HIV; HIV Infections; Humans; Piperidines; Purines; Receptors, Estrogen; Roscovitine; Topoisomerase I Inhibitors; Virus Replication | 2004 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Flavonoids; Glomerulonephritis; Hematologic Neoplasms; HIV Infections; Humans; Molecular Sequence Data; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic | 2005 |
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Drug Evaluation, Preclinical; Flavonoids; Gene Expression Regulation; Humans; Mutation; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic; Tumor Suppressor Protein p53 | 2006 |
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
Topics: Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Flavonoids; Gene Expression Regulation, Viral; HIV Infections; Humans; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Virus Replication | 2006 |
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Neoplasms; Piperidines; Purines; Roscovitine; Staurosporine | 2007 |
Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof.
Topics: Flavonoids; HIV Infections; HIV-1; Humans; Models, Biological; Piperidines; Positive Transcriptional Elongation Factor B; Protein Kinase Inhibitors; Purines; RNA, Small Nuclear; Roscovitine; Transcription, Genetic | 2009 |
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
Recent advances in CDK inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Flavonoids; Humans; Molecular Structure; Piperidines; Protein Kinase Inhibitors; Roscovitine; Signal Transduction | 2018 |
32 other study(ies) available for cyc 202 and alvocidib
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Female; Humans; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Phosphorylation; Protein Binding; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Topics: Cell Line, Tumor; Cell Proliferation; Crystallization; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Recombination, Genetic; Roscovitine; Spectrophotometry, Infrared | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
Topics: Animals; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinase 5; Flavonoids; Fluorine; Hippocampus; Humans; Hydrogen Bonding; Mice; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Triazoles | 2011 |
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Topics: Cyclin-Dependent Kinase 9; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2013 |
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Topics: Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2013 |
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Protein Kinases; Pyridines; Pyrimidines; Repressor Proteins; Structure-Activity Relationship | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Structure-Activity Relationship | 2021 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamides; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Differentiation; Cell Survival; Cerebellum; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Cytarabine; Enzyme Inhibitors; Flavonoids; Imatinib Mesylate; Imidazoles; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinases; Neurons; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Purines; Pyridines; Pyrimidines; Rats; Roscovitine; Signal Transduction; Stress, Physiological; Wortmannin | 1999 |
Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
Topics: Carcinoma, Non-Small-Cell Lung; CDC2-CDC28 Kinases; Cell Differentiation; Cell Division; Cyclin D; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Flavonoids; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Piperidines; Protein Serine-Threonine Kinases; Purines; Roscovitine; Signal Transduction; Transfection; Tumor Cells, Cultured | 1999 |
Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes.
Topics: Animals; Apoptosis; Cell Differentiation; Cells, Cultured; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Genes, Viral; HIV Infections; HIV-1; Kidney; Mice; Piperidines; Purines; Roscovitine; Transcription, Genetic | 2001 |
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Topics: 2-Aminopurine; Antineoplastic Agents; Apoptosis; Chromones; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Leukemia; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Roscovitine; Tumor Cells, Cultured | 2003 |
Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Animals, Newborn; Anthracenes; Anti-Bacterial Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Bromodeoxyuridine; Carrier Proteins; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Count; Cell Survival; Cells, Cultured; Cerebellum; Chromatin; Colchicine; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Flavonoids; Flow Cytometry; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Kainic Acid; MAP Kinase Kinase 4; Microtubules; Minocycline; Mitogen-Activated Protein Kinase Kinases; Neurons; Neuroprotective Agents; Piperidines; Purines; Rats; Rats, Sprague-Dawley; Roscovitine; Time Factors; Tubulin | 2003 |
Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Topics: Amino Acid Sequence; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Drug Design; Flavonoids; Humans; Hydrogen Bonding; Models, Chemical; Models, Molecular; Molecular Sequence Data; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Roscovitine; Sequence Homology, Amino Acid | 2004 |
E2F4 deficiency promotes drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; E2F4 Transcription Factor; Fibroblasts; Flavonoids; Humans; Lung Neoplasms; Mice; Mice, Knockout; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; RNA, Small Interfering; Roscovitine; Thiazoles; Transcription Factors; Tumor Cells, Cultured | 2004 |
Role of the cell cycle in the pathobiology of central nervous system trauma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain; Cell Cycle; Cell Proliferation; Cell Survival; Cells, Cultured; Central Nervous System; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Etoposide; Flavonoids; Kinetin; Magnetic Resonance Spectroscopy; Microglia; Mitosis; Neurons; Piperidines; Purines; Rats; Roscovitine; Up-Regulation | 2005 |
Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.
Topics: Cyclin-Dependent Kinases; Drug Evaluation; Flavonoids; HIV-1; Humans; Indoles; Inhibitory Concentration 50; Leukocytes, Mononuclear; Macrophages; Oximes; Piperidines; Positive Transcriptional Elongation Factor B; Protein Kinase Inhibitors; Purines; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; U937 Cells; Virus Replication | 2005 |
Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Cyclin D1; Cyclin E; Cyclin-Dependent Kinases; Flavonoids; Kinetin; Mice; Mitosis; Motor Neurons; Nerve Growth Factors; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine | 2006 |
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex.
Topics: Cyclin-Dependent Kinase 9; Dichlororibofuranosylbenzimidazole; Enzyme Inhibitors; Flavonoids; HIV-1; Kinetics; Piperidines; Positive Transcriptional Elongation Factor B; Purines; Roscovitine; Viral Proteins; Virus Replication | 2007 |
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Caspases; Cyclin-Dependent Kinases; Female; Flavonoids; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Membrane Potential, Mitochondrial; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Thiazoles; Transcription, Genetic; X-Linked Inhibitor of Apoptosis Protein | 2009 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons.
Topics: Animals; Apoptosis; Cells, Cultured; Cerebellum; Cyclin-Dependent Kinases; Cytoprotection; Dose-Response Relationship, Drug; Flavonoids; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Neurons; Neuroprotective Agents; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-jun; Purines; Rats; Rats, Sprague-Dawley; Roscovitine; Signal Transduction | 2012 |
Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Topics: Apoptosis; Cells, Cultured; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Flavonoids; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neutrophils; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine | 2012 |
Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.
Topics: Apoptosis; Cell Line, Tumor; Cyclin D1; Cyclin E; Flavonoids; Gene Expression Profiling; Gene Expression Regulation; Gene Silencing; Genomic Instability; Humans; Multiple Myeloma; Oncogene Proteins; Piperidines; Protein Kinase Inhibitors; Purines; RNA, Small Interfering; Roscovitine | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
CDK7 is a component of the integrated stress response regulating SNAT2 (SLC38A2)/System A adaptation in response to cellular amino acid deprivation.
Topics: Activating Transcription Factor 4; Amino Acid Transport System A; Amino Acids; Aminophenols; Animals; Cell Line; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Flavonoids; HEK293 Cells; HeLa Cells; Humans; Maleimides; Phenylenediamines; Piperidines; Protein Serine-Threonine Kinases; Pyrimidines; Rats; Roscovitine; Stress, Physiological | 2019 |